what is the newest glp 1 Understanding GLP-1 pills: A new weight loss alternative to injections With FDA approval of Wegovy

Description

Motility issues are at the heart of so many gut diseases and problems

Read More: #GLP1 #GLP1Market #Semaglutide #Tirzepatide #Ozempic #Wegovy #Mounjaro #Zepbound #ObesityTreatment #WeightLossDrugs #DiabetesMarket #PharmaMarket #HealthcareIndustry #Biotechnology #MarketResearch #LifeSciences #HealthcareTrends #DrugDevelopment #PharmaceuticalIndustry #MarketAnalysis | 10 comments on LinkedIn

Key Findings: - Increased risk of going over recommended weight gain limits - Higher chances of preterm birth (from 13% to 17%) - Rising cases of gestational diabetes (15% to 20%) - Nearly half faced high blood pressure issues While baby sizes and C-section rates remained similar, the impact on maternal health is significant

With the successive launch of Glucagon-like peptide-1 (GLP-1) class drugs that allow weight loss with a once-daily pill instead of an injection, the barrier to obesity treatment is lowering